Setting “artificial constraints” on the number of pivotal trials required to support a drug’s approval could detract from the ...

EFSA has cleared its first CBD novel food, a synthetic ingredient from Chanelle McCoy, but at just 2mg a day for over-25s.

The Chinese government's new five-year economic plan includes multiple specific aspects and goals for the biopharma ...

California law which took effect in July included supplements as food products required to “use by” or “best used by” on ...

We are delighted to announce the shortlist for the Annual Scrip Awards. Now in their 22nd year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied ...

The surprise backing of two industry-aligned former FDA commissioners who have clashed with the Trump Administration on ...

The company announced it had raised $311m in a series E funding round, which it plans to use to move its lead candidates into ...

HHS requested public comments on potential changes to regulating unmodified deceased donor islet cells, including ...

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

A New York federal court has dismissed an Entresto antitrust suit, finding Novartis properly listed the disputed ’659 patent in the Orange Book despite arguments that it did not specifically claim the ...

Speaking to Generics Bulletin after Sandoz unveiled its Bio 100 long-term strategy, chief commercial officer Rebecca Guntern discusses the significance of both small-molecule generics and biosimilars ...

Simcere president Yunshu Zhou pinpoints Chinese firm’s next steps in deal making, based on a renewed R&D rationale in a global context.